Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
Business websites
JNJ.com
NewPharm.com
JnJMedTech.com
J&J MedTech
US • English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
Switzerland
English
Switzerland
Français
US
English
United Kingdom
English
Latest News
Back
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Back
Discover J&J
Back
Our Credo
Our Leadership
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Innovative Medicine
MedTech
Our societal impact
Back
Global Community Impact
Global Public Health
Global environmental sustainability
Suppliers
Back
Responsible Supply Base
Supplier Enabled Innovation
Supplier Resources
Careers
Back
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Investors
Back
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Latest News
Back
Innovation
Caring & giving
Personal stories
Health & wellness
Our heritage
Our Company
Back
Discover J&J
Back
Our Credo
Our Leadership
Code of Business Conduct
Corporate Reports
Diversity, Equity & Inclusion
ESG Policies & Positions
Innovation at J&J
Digital Solutions
J&J Health & Wellness Solutions
Office of the Chief Medical Officer
Veterans, Military & Military Families
Innovative Medicine
MedTech
Our societal impact
Back
Global Community Impact
Global Public Health
Global environmental sustainability
Suppliers
Back
Responsible Supply Base
Supplier Enabled Innovation
Supplier Resources
Careers
Back
Life at J&J
Diversity, Equity and Inclusion
Career Areas of Impact
Students
Re-Ignite Program
Contract & Freelance Partner Opportunities
Career Stories
Investors
Back
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Search Query
Submit Search
Dictate search request
Recently Viewed
Listening...
Show Search
Menu
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Dictate search request
Listening...
1,914 Results
Date
All Dates (1914)
Past 30 days (15)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1914)
Corporate (131)
ESG (1)
Financial (282)
Global Public Health (58)
Leadership (20)
Medical technologies (257)
Pharmaceuticals (859)
Research (42)
1,914 results
Filters
Date
All Dates (1914)
Past 30 days (15)
2023 (140)
2022 (125)
2021 (185)
2020 (110)
2019 (130)
2018 (166)
2017 (196)
2016 (125)
Topic
All (1914)
Corporate (131)
ESG (1)
Financial (282)
Global Public Health (58)
Leadership (20)
Medical technologies (257)
Pharmaceuticals (859)
Research (42)
Sort By:
Newest
Newest
Relevance
Oldest
March 28, 2024
CERENOVUS Expands Minimally Invasive Stroke Care Innovation with New Liquid Embolic System Procedural Set
CERENOVUS launches TRUFILL™ n-BCA Liquid Embolic System Procedural Set Design Addresses Real-World Challenges in Treatment of Hemorrhagic Stroke
Read more
March 26, 2024
Johnson & Johnson’s nipocalimab granted U.S. FDA Fast Track designation to reduce the risk of fetal neonatal alloimmune thrombocytopenia (FNAIT) in alloimmunized pregnant adults
FNAIT is a rare disease that occurs when a pregnant person’s immune system attacks fetal platelets, resulting in the risk of internal bleeding, which can be life threatening to the fetus or newborn The Phase 3 FREESIA program is underway and nipocalimab is the only investigational therapy currently reported to be in clinical development for the treatment of FNAIT
Read more
March 22, 2024
U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)
OPSYNVI® combines two proven treatments with established efficacy and safety profiles into one tablet to be taken once daily, offering an option that helps to support the implementation of clinical guideline recommendations for early use of combination therapy.1 The comprehensive PAH portfolio at Johnson & Johnson now includes treatments that address all three foundational and guideline-recommended pathways for this rare, progressive disease.2 Approval is based on the results from the pivotal Phase 3 A DUE study, which met its co-primary endpoints, demonstrating significant pulmonary hemodynamic improvement.1
Read more
March 19, 2024
U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1
This approval offers a new HIV-1 treatment option for children in the U.S. at least 2 years of age, weighing 14 kg – 25 kg and living with HIV
Read more
March 18, 2024
Johnson & Johnson MedTech working with NVIDIA to scale AI for surgery
Johnson & Johnson MedTech is working with NVIDIA on how its technologies can accelerate secure, real-time analysis of surgical data at the edge Johnson & Johnson MedTech will enable AI-based model development and application deployment, providing a path to scale within its connected digital ecosystem for surgery
Read more
March 18, 2024
RYBREVANT® (amivantamab-vmjw) data at ELCC advance Johnson & Johnson’s ambition to transform the standard of care for patients with EGFR-mutated non-small cell lung cancer
Featured data include new results from the Phase 3 MARIPOSA study, which has received U.S. FDA Priority Review, and the Phase 1b PALOMA study of subcutaneous amivantamab
Read more
March 15, 2024
U.S. FDA Oncologic Drugs Advisory Committee recommends CARVYKTI® (ciltacabtagene autoleucel) for the earlier treatment of patients with relapsed or refractory multiple myeloma
FDA ODAC unanimously votes 11 to 0 supporting favorable risk-benefit assessment of CARVYKTI® based on results from the Phase 3 CARTITUDE-4 study
Read more
March 11, 2024
Johnson & Johnson submits supplemental Biologics License Application to U.S. FDA seeking approval of TREMFYA®(guselkumab) for the treatment of adults with moderately to severely active ulcerative colitis
Submission is supported by data from the Phase 3 QUASAR program, which showed a significantly greater percentage of patients with moderately to severely active ulcerative colitis who received TREMFYA® achieved clinical remission at Week 44 compared with placebo
Read more
March 11, 2024
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
Read more
March 9, 2024
New data shows JNJ-2113, the first and only investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
JNJ-2113 long-term extension FRONTIER 2 study demonstrated sustained efficacy from Week 16 to Week 52 and safety results consistent with previously reported data (FRONTIER 1 Study) in a late-breaking oral presentation at the American Academy of Dermatology 2024 Annual Meeting
Read more
Load More
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue